Iovance Biotherapeutics, Nio, NetEase And Other Big Stocks Moving Lower On Wednesday

U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday.

Shares of Iovance Biotherapeutics, Inc. IOVA fell sharply during Wednesday’s session after the company announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).

The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
Iovance Biotherapeutics shares dipped 20.4% to $7.07 on Wednesday.

Here are some other big stocks recording gains in today’s session.

  • Nukkleus Inc. NUKK shares declined 28.8% to $2.60 after jumping around 11% on Tuesday.
  • GreenTree Hospitality Group Ltd. GHG fell 10% to $3.69.
  • InnSuites Hospitality Trust IHT dipped 8.6% to $1.4250.
  • LanzaTech Global, Inc. LNZA fell 7.6% to $5.00.
  • Life Time Group Holdings, Inc. LTH fell 6.9% to $14.30. On Dec 22, Life Time Group Holdings agreed with company’s CFO, Robert Houghton that he will resign as CFO.
  • Cheche Group Inc. CCG fell 6.3% to $6.51.
  • Canopy Growth Corporation CGC declined 6.2% to $5.31.
  • Velocity Financial, Inc. VEL fell 4.8% to $15.62.
  • The Beauty Health Company SKIN fell 4.8% to $3.0850.
  • NetEase, Inc. NTES fell 4.2% to $88.30 on continued volatility amid regulatory developments in China's gaming sector.
  • NIO Inc. NIO fell 4.1% to $8.95 after rising more than 10% on Tuesday. Nio stock raced higher to start the week after the company launched its new ET9 sedan at its Nio Day event over the weekend.

 

Now Read This: Ethereum Moves Higher; Bitcoin SV Emerges As Top Gainer

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading Ideasbig losersTop Losers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...